EyePoint, Inc. (EYPT) stock
EYPTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
$0.30−0.01 (-3.80%)
Close on Nov 17, 2026Market cap $25.51MP/E –Yield –
EyePoint r&d expenses
Research and development expenses are spending on new products and technology.
EyePoint's R&D Expenses for the twelve months ending Jun 30, 2026 was $262.73M, up 40.5% year over year. For fiscal 2025 it was $221.04M, up 66.3% from the year before. Over ten years it grew 36.9% a year on average. The highest annual figure on record is $221.04M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $221.04M | +66.3% |
| FY2024 | Dec 31, 2024 | $132.93M | +105.6% |
| FY2023 | Dec 31, 2023 | $64.66M | +30.3% |
| FY2022 | Dec 31, 2022 | $49.64M | +74.2% |
| FY2021 | Dec 31, 2021 | $28.50M | +63.6% |
| FY2020 | Dec 31, 2020 | $17.42M | +7.7% |
| FY2018 | Jun 30, 2018 | $16.18M | +8.7% |
| FY2017 | Jun 30, 2017 | $14.88M | +3.5% |
| FY2016 | Jun 30, 2016 | $14.38M | +19.0% |
| FY2015 | Jun 30, 2015 | $12.09M | +26.3% |
| FY2014 | Jun 30, 2014 | $9.57M | +36.7% |
| FY2013 | Jun 30, 2013 | $7.01M | -0.5% |
| FY2012 | Jun 30, 2012 | $7.04M | +2.5% |
| FY2011 | Jun 30, 2011 | $6.86M | -1.9% |
| FY2010 | Jun 30, 2010 | $6.99M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $83.61M | +50.7% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $72.15M | +23.2% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $59.21M | +36.5% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $47.75M | +61.6% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $55.50M | +86.1% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $58.57M | +94.3% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $43.37M | +141.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $29.54M | +70.1% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $29.82M | +89.6% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $30.14M | +121.3% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $17.95M | +15.5% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $17.36M | +55.6% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $15.73M | +21.1% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $13.62M | +36.9% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $15.54M | +74.3% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $11.16M | +31.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $12.99M | +131.8% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $9.95M | +81.5% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $8.92M | +71.3% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $8.50M | +107.8% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $5.61M | +71.1% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $5.48M | +12.9% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $5.21M | +9.2% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $4.09M | +23.0% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $3.28M | -23.3% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $4.85M | +27.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $4.77M | +13.1% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $3.33M | +0.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $4.27M | +34.9% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $3.82M | -8.6% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $4.21M | +2.7% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $3.32M | +8.1% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $3.17M | -14.9% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $4.18M | +20.0% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $4.10M | +28.3% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $3.07M | -7.9% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $3.72M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $3.48M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $3.20M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $3.34M | – |
See a number that looks wrong?